Malaria
Conditions
Interventions
Dihydroartemisinin-Piperaquine
Sponsors
Babcock University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Pregnant women ¿18years old, 16-28weeks gestational age at enrollment, living within the study vicinity and willing to deliver at the study site facility, had no anti-malarial,tetracycline or sulphonamide-derivative drugs within the preceding seven days,who give consent.
Exclusion criteria
Exclusion criteria: Pregnant women who do not meet the inclusion criteria, HIV-positive women, hypersensitivity to any of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Prevalence of placental malaria diagnosed histopathologically by parasite presence;-Incidence of maternal malaria infection by day 28 post-IPT diagnosed by clinical and parasitological methods | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of: maternal anemia,spontaneous miscarriage,preterm delivery,low birth weight,still birth,congenital anomalies,neonatal death;-Prevalence of resistance markers on molecular analysis;-Plasma drug concentration ;-Drug tolerability and incidence of adverse events | — |
Countries
Nigeria
Contacts
Public ContactOladapo Walker
Professor of Pharmacology, Babcock University
Outcome results
None listed